Processa Pharmaceuticals, Inc.
PCSA
$0.26
-$0.01-2.52%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -1.53% | -30.68% | -3.96% | -13.46% | -62.57% |
| Total Depreciation and Amortization | 50.00% | 200.00% | 200.00% | 200.00% | 100.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 85.81% | 30.36% | 32.65% | -36.11% | 7.77% |
| Change in Net Operating Assets | 4.77% | 381.89% | -129.98% | 9,680.65% | -350.35% |
| Cash from Operations | 3.28% | 32.14% | -33.23% | -5.83% | -104.59% |
| Capital Expenditure | -- | -- | -- | -- | -14.29% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -14.29% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -171.43% | 7.14% | -66.67% | -- | -- |
| Issuance of Common Stock | 207.09% | -- | -29.35% | -- | -- |
| Repurchase of Common Stock | 100.00% | -350.00% | 92.43% | 99.02% | 92.98% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 208.38% | 185,688.24% | -29.18% | 1,889.54% | 1,857.50% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 76.56% | 220.61% | -59.52% | 21.09% | -47.52% |